Skip to main content
. 2021 Aug 28;10(17):3864. doi: 10.3390/jcm10173864

Figure 6.

Figure 6

Serum biomarkers concentrations in IPF patients with stable and progressive disease over the first year of anti-fibrotic therapy. Notes: Panels showing serum biomarkers concentrations measured at baseline and 12-month timepoint for: (A) KL-6, (B) SP-D, (C) MMP-7, (D) CA19-9, (E) CA-125, (F) CCL18, (G) periostin. * p < 0.05. Abbreviations: KL-6—Krebs von den Lungen-6, SP-D—surfactant protein D, MMP-7—matrix metalloproteinase 7, CA19-9—cancer antigen 19-9, CA-125—cancer antigen 125, CCL18—chemokine (C-C motif) ligand 18, IPF—idiopathic pulmonary fibrosis.